Literature DB >> 3780841

Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers.

R Lambe, O Kennedy, M Kenny, A Darragh.   

Abstract

The tolerance and diuretic properties of torasemide after oral or intravenous administration to healthy volunteers were studied. Six groups, each of 6 subjects, were given single rising oral doses ranging from 10 to 100 mg; 8 subjects received ascending i.v. doses on alternate days, ranging from 2.5 to 80 mg. At the highest oral doses investigated (80 mg and 100 mg) a number of volunteers complained of cramps in the knees, calves and feet. These symptoms were generally of short duration. Similar effects were not encountered during the intravenous study. There were no significant changes in ECG. Some significant drug-related changes were encountered in the within-study biochemistry and haematology assessments. Torasemide proved to be a potent diuretic following oral administration at all the doses investigated and following intravenous administration at all doses except 2.5 mg. A linear relationship existed between the urine output and the logarithm of the dose, and both sodium and chloride excretion were linearly correlated with urine volume. The rate of potassium excretion was markedly lower than that of sodium and chloride and was linearly correlated with the logarithm of the urine volume. Torasemide was well tolerated from all perspectives studied. It showed a potent diuretic property, and was equally effective by the oral and intravenous routes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780841     DOI: 10.1007/bf00541461

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Bumetanide--acute and long term studies of a new high potency diuretic.

Authors:  W R Murdoch; W H Auld
Journal:  Postgrad Med J       Date:  1975-01       Impact factor: 2.401

2.  Time course of changes in concentration of some plasma components after frusemide.

Authors:  T O Haug
Journal:  Br Med J       Date:  1976-09-11

3.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.

Authors:  D L Davies; A F Lant; N R Millard; A J Smith; J W Ward; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

5.  Factors affecting urate excretion following diuretic administration in man.

Authors:  T H Steele; S Oppenheimer
Journal:  Am J Med       Date:  1969-10       Impact factor: 4.965

6.  Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect.

Authors:  M Lesne; F Clerckx-Braun; P Duhoux; C van Ypersele de Strihou
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-08

7.  Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects.

Authors:  Y Ambroes; I Ronflette; L Dodion
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Diuretic and antihypertensive actions of furosemide.

Authors:  D E Hutcheon; G Leonard
Journal:  J Clin Pharmacol J New Drugs       Date:  1967 Jan-Feb

9.  Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects.

Authors:  C J Roberts; M Homeida; F Roberts; W Bogie
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

  9 in total
  7 in total

Review 1.  Low dose loop diuretics in essential hypertension. Experience with torasemide.

Authors:  I Achhammer; P Metz
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  Torasemide. A review of its pharmacological properties and therapeutic potential.

Authors:  H A Friedel; M M Buckley
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 3.  An evaluation of torsemide in patients with heart failure and renal disease.

Authors:  Anthony E Peters; Robert J Mentz; Tracy A DeWald; Stephen J Greene
Journal:  Expert Rev Cardiovasc Ther       Date:  2022-01-03

Review 4.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 5.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

6.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

7.  Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.

Authors:  Maria Rosa Ballester; Eulàlia Roig; Ignasi Gich; Montse Puntes; Joaquín Delgadillo; Benjamín Santos; Rosa Maria Antonijoan
Journal:  Drug Des Devel Ther       Date:  2015-08-05       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.